Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation
NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the Company has initiated an expanded access program at Massachusetts General Hospital (MGH) to provide its investigational drug, BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), to critically ill patients diagnosed with COVID-19 in the intensive care unit ("ICU") that may require calming or arousable sedation.
We are pleased to support clinicians at MGH as they manage an in-flux of COVID-19 patients, commented Vimal Mehta, Ph.D., Chief Executive Officer of BTI. COVID-19 primarily affects the respiratory system, with the severely ill often requiring mechanical ventilation. As a result of critical illness and the medical coma that is necessary for mechanical ventilation, patients frequently develop delirium and agitation, causing worse clinical outcomes and extended hospital stays. BXCL501 is being studied in advanced clinical trials to treat acute agitation, and we believe it has the potential, if approved, to help physicians treat patients that may be struggling with agitation or delirium.
Facilitated by the U.S. Food and Drug Administration (FDA), expanded access, also known as compassionate use, provides an opportunity for patients to receive an investigational treatment prior to regulatory approval when there are no comparable or satisfactory therapeutic alternatives available.
Being on the frontlines of this pandemic, our intensivists have witnessed firsthand the high numbers of critically ill patients diagnosed with COVID-19 and ICU delirium, added Seun Johnson-Akeju, M.D., M.M.Sc., Anesthetist-in-Chief of the Department of Anesthesia, Critical Care and Pain Medicine at the Massachusetts General Hospital. The COVID-19 surge caused an acute shortage of medications for managing agitation. We are hopeful that BXCL501 will improve the clinical outcomes of critically ill patients diagnosed with COVID-19 that are struggling with agitation and ICU delirium.
About BXCL501
BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of mild to moderate agitation in schizophrenia, bipolar disorder, and dementia.
A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in the Phase 1b/2 TRANQUILITY trial for the treatment of agitation associated with dementia, as well as the Phase 1b/2 RELEASE trial for the treatment of opioid withdrawal symptoms.
About BioXcel Therapeutics, Inc.:
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the evaluation of the Companys investigational drug, BXCL501, in the treatment of COVID-19 patients. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.
BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by its Current Report on Form 8-K filed on April 14, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov and the Investors page of its website atwww.bioxceltherapeutics.com.
These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.
Contact Information:BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com
Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942
Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967
- Cristina Savin and Tim Vogels discuss how AI has shaped their neuroscience research - The Transmitter: Neuroscience News and Perspectives - October 13th, 2024 [October 13th, 2024]
- Should I stay (and eat) or should I go? How the brain balances hunger with competing drives - The Transmitter: Neuroscience News and Perspectives - October 13th, 2024 [October 13th, 2024]
- How neuroscience comics add KA-POW! to the field: Q&A with Kanaka Rajan - The Transmitter: Neuroscience News and Perspectives - October 13th, 2024 [October 13th, 2024]
- Neuroscience research sheds light on how psilocybin alters spatial awareness - PsyPost - October 13th, 2024 [October 13th, 2024]
- Newly Discovered Protein Complex Shapes Synapses and Mental Health - Neuroscience News - October 13th, 2024 [October 13th, 2024]
- The Neuroscience Behind Immersive Filmmaking - Raindance - October 13th, 2024 [October 13th, 2024]
- What are mechanisms? Unpacking the term is key to progress in neuroscience - The Transmitter: Neuroscience News and Perspectives - October 13th, 2024 [October 13th, 2024]
- Kentucky neuroscience doctor honored with national distinction - wnky.com - October 13th, 2024 [October 13th, 2024]
- Cell X Technologies and Aspen Neuroscience collaborate to address throughput and scalability in manufacturing automation to facilitate iPSC cell... - October 13th, 2024 [October 13th, 2024]
- Tracking Daily Habits Lasting Effects on the Brain - Neuroscience News - October 13th, 2024 [October 13th, 2024]
- Dak Prescott Was Silent After Hearing It From a Teammate. Its a Lesson in Emotional Intelligence (Backed By Neuroscience) - Inc. - October 13th, 2024 [October 13th, 2024]
- Helping Kids Fact-Check in the Age of Misinformation - Neuroscience News - October 13th, 2024 [October 13th, 2024]
- Study Links Calorie Restriction to Longevity - Neuroscience News - October 13th, 2024 [October 13th, 2024]
- A Princeton Professor Walks into a Neuroscience Meeting -- Many Years Later It Leads to a Nobel Prize in Physics - TAPinto.net - October 13th, 2024 [October 13th, 2024]
- Try these neuroscience-backed tactics to train your brain to make better decisions - Fast Company - October 2nd, 2024 [October 2nd, 2024]
- Tips to navigate SfN as a trainee - The Transmitter: Neuroscience News and Perspectives - October 2nd, 2024 [October 2nd, 2024]
- Neuroscience Says This 10-Minute Brain Exercise Will Make You Mentally Sharper and Keep You Focused All Day - Inc. - October 2nd, 2024 [October 2nd, 2024]
- Successful people do this 1 thing to be 'happier, more productive, less stressed' at work, says CEO and neuroscience researcher - CNBC - October 2nd, 2024 [October 2nd, 2024]
- Utilizing the Power of Neuroscience, Isabella Kensington May Have Cracked the Code Between Music and Healing - AOL - October 2nd, 2024 [October 2nd, 2024]
- Steve Jobs swore the 10-minute rule made him smarter. Modern neuroscience is discovering he was right - The Star Online - October 2nd, 2024 [October 2nd, 2024]
- Steve Jobs Swore the 10-Minute Rule Made Him Smarter. Modern Neuroscience Is Discovering He Was Right - Inc. - October 2nd, 2024 [October 2nd, 2024]
- Neural manifolds: Latest buzzword or pathway to understand the brain? - The Transmitter: Neuroscience News and Perspectives - October 2nd, 2024 [October 2nd, 2024]
- Neuroscience Says 3 Brainy Habits Will Make You More Efficient, Productive, and Focused - Inc. - October 2nd, 2024 [October 2nd, 2024]
- Ethics, AI, and Neuroscience Converge at Mental Health, Brain, and Behavioral Science Research Day - The University of Utah - October 2nd, 2024 [October 2nd, 2024]
- The neuroscience of campus memories - The Stanford Daily - October 2nd, 2024 [October 2nd, 2024]
- How the Brain Enhances Sleep Through Synaptic Strength - Neuroscience News - October 2nd, 2024 [October 2nd, 2024]
- Neanderthoids and space brains: Stem cell researcher pushes the boundaries of neuroscience - Medical Xpress - October 2nd, 2024 [October 2nd, 2024]
- Nancy Padilla-Coreano - The Transmitter: Neuroscience News and Perspectives - October 2nd, 2024 [October 2nd, 2024]
- Utilizing the Power of Neuroscience, Isabella Kensington May Have Cracked the Code Between Music and Healing - Spin - October 2nd, 2024 [October 2nd, 2024]
- Genetic Variants Linked to Alzheimers Trigger Inflammation in Females - Neuroscience News - October 2nd, 2024 [October 2nd, 2024]
- New Astrocyte Target for Alzheimers Therapy - Neuroscience News - October 2nd, 2024 [October 2nd, 2024]
- Is an ankle sprain also a brain injury? How neuroscience is helping athletes, astronauts and average Joes - The Conversation Indonesia - October 2nd, 2024 [October 2nd, 2024]
- 5 Brain Strategies to Dramatically Reduce Conflict and Boost Your Leadership, Backed by Neuroscience - Inc. - September 23rd, 2024 [September 23rd, 2024]
- Fascinating neuroscience research reveals a key mechanism underlying human cognition - PsyPost - September 23rd, 2024 [September 23rd, 2024]
- Averaging is a convenient fiction of neuroscience - The Transmitter: Neuroscience News and Perspectives - September 23rd, 2024 [September 23rd, 2024]
- Repeat scans reveal brain changes that precede childbirth - The Transmitter: Neuroscience News and Perspectives - September 23rd, 2024 [September 23rd, 2024]
- Neuroscience helps explain the teenage brain and mental health - ABC News - September 15th, 2024 [September 15th, 2024]
- XX Marks the Spot: Addressing Sex Bias in Neuroscience - The Scientist - September 15th, 2024 [September 15th, 2024]
- Neuroscience-based tools for transformative leadership - Fast Company - September 15th, 2024 [September 15th, 2024]
- How 100 Years of EEG Have Transformed Neuroscience - Being Patient - September 15th, 2024 [September 15th, 2024]
- Reconstructing dopamines link to reward - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- The neuroscience of itch in relation to transdiagnostic psychological approaches - Nature.com - September 15th, 2024 [September 15th, 2024]
- A README for open neuroscience - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Dopamine and the need for alternative theories - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Kim Stachenfeld on the dance between neuroscience and artificial intelligence - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Vijay Mohan K. Namboodiri - The Transmitter: Neuroscience News and Perspectives - September 15th, 2024 [September 15th, 2024]
- Varied Cognitive Training Boosts Learning and Memory - Neuroscience News - September 15th, 2024 [September 15th, 2024]
- Issue | September 2024 | XX Marks the Spot: Addressing Sex Bias in Neuroscience - The Scientist - September 15th, 2024 [September 15th, 2024]
- The Transmitter Partners With World Wide Neuro and Brain Inspired, Building on Mission to Inform, Connect Neuroscience Community - StreetInsider.com - September 15th, 2024 [September 15th, 2024]
- Gene Therapy Offers Hope for Glaucoma and AMD - Neuroscience News - September 15th, 2024 [September 15th, 2024]
- The Neuroscience of Phantom Sensations: Can We Feel Whats Not Really There? - SciTechDaily - September 2nd, 2024 [September 2nd, 2024]
- Tau May Protect Brain Cells from Oxidative Damage - Neuroscience News - September 2nd, 2024 [September 2nd, 2024]
- Scientists use fainting to uncover new insights into the neuroscience of consciousness - PsyPost - September 2nd, 2024 [September 2nd, 2024]
- Biosensors and being fearless with Lin Tian - The Transmitter: Neuroscience News and Perspectives - September 2nd, 2024 [September 2nd, 2024]
- Can Neuroscience Train Your Brain to Be Happier? This Startup Has an App for That - Inc. - September 2nd, 2024 [September 2nd, 2024]
- Neuroscience Surprise: Different Types of Love Light Up Different Parts of the Brain - SciTechDaily - September 2nd, 2024 [September 2nd, 2024]
- Second paper from lab of Nobel Prize winner to be retracted - The Transmitter: Neuroscience News and Perspectives - September 2nd, 2024 [September 2nd, 2024]
- How cognitive bias affects your draft strategy with neuroscience professor Dr. Renee Miller - Yahoo Sports - August 5th, 2024 [August 5th, 2024]
- This 3-step approach to performance reviews uses neuroscience to make them less awful - Fast Company - August 5th, 2024 [August 5th, 2024]
- Is it time to worry about brain chimeras? - The Transmitter: Neuroscience News and Perspectives - August 5th, 2024 [August 5th, 2024]
- Sharing brain images can foster new neuroscience discoveries - American Heart Association - July 26th, 2024 [July 26th, 2024]
- Latest News: Neuroscience Major Applies What Shes Learned in the Classroom and in the Lab - Muhlenberg College - July 26th, 2024 [July 26th, 2024]
- BioIVT to Highlight its Integral Role in Drug and Diagnostic Discovery and Development in addition to Neuroscience Research at Premier Life Science... - July 26th, 2024 [July 26th, 2024]
- Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision... - July 26th, 2024 [July 26th, 2024]
- Neuroscience Says 3 Simple Steps Can Turn Disappointment and Stress Into Success and Fulfillment (and Boost Your Emotional Intelligence) - Inc. - July 26th, 2024 [July 26th, 2024]
- Golf: neuroscience reveals the secrets of better putting new study - The Conversation - July 26th, 2024 [July 26th, 2024]
- The Neuroscience Behind Video: Why Video is the Most Effective Marketing Channel - StreamTV Insider - July 26th, 2024 [July 26th, 2024]
- Building an autism research registry: Q&A with Tony Charman - The Transmitter: Neuroscience News and Perspectives - July 26th, 2024 [July 26th, 2024]
- Adjusting Proteins Increases Ozempics Effectiveness - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Low-Calorie Diets Harm Athletes Performance and Health - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Reflective Thinking Boosts Teen Brain Resilience to Violence - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Neuroscience Says Olympians Like Simone Biles Use the Autopilot Trick to Achieve Peak Performance. So Can You - Inc. - July 18th, 2024 [July 18th, 2024]
- What well-being is (and isnt), according to neuroscience - Big Think - July 18th, 2024 [July 18th, 2024]
- Brain Areas Take Micro-Naps While the Rest Stays Awake - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Persistent protein pairing enables memories to last - The Transmitter: Neuroscience News and Perspectives - July 18th, 2024 [July 18th, 2024]
- AI Enhances Story Creativity but Risks Reducing Novelty - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Infection Brain Inflammation Triggers Muscle Weakness - Neuroscience News - July 18th, 2024 [July 18th, 2024]
- Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of Buy from Analysts - Defense World - July 18th, 2024 [July 18th, 2024]
- 2024 Kavli Prize awarded for research on face-selective brain areas - The Transmitter: Neuroscience News and Perspectives - June 18th, 2024 [June 18th, 2024]
- Unlocking Flow: The Neuroscience of Creative Bliss - Neuroscience News - April 15th, 2024 [April 15th, 2024]